Li Stephen, Tomalin Anne
Humber College of Applied Arts and Technology, Regulatory Affairs Program, Toronto, Ontario, Canada.
J Pharm Pharm Sci. 2002 Jan-Apr;5(1):5-11.
Many industries are affected by the stale global economy recently. However, the innovative pharmaceutical and biotechnology industry seems to be relentlessly producing a wealth of newer therapeutic products to meet the increasing demand of the aging population. These companies" abilities to produce safer and more effective products are the results of research and development (R&D) spending. Clearly, by investigating R&D expenditures of patentees, one can paint a better picture of the condition in this sector of the Canadian economy.
To track patentees R&D expenditures, the Patented Medicine Prices Review Board (PMPRB) annual reports have become the primary sources of data. Furthermore, the financial market and the Therapeutic Directorate Annual Drug Submission Performance Report have also been used to address some of the patterns that are seen in PMPRB data.
Most of the data suggest excellent growth in the innovative pharmaceutical and biotechnology sector in Canada. Despite this growth, it still lags behind the demand of newer therapeutic products. Nevertheless, the industry can weather a volatile economy well.
Patentees R&D expenditure is a good indicator of the health in the industry. It provides a perspective not only within Canada itself, but also globally.
许多行业最近都受到全球经济不景气的影响。然而，创新制药和生物技术行业似乎在不懈地生产大量更新的治疗产品，以满足老龄化人口不断增长的需求。这些公司生产更安全、更有效产品的能力是研发支出的结果。显然，通过调查专利权人的研发支出，可以更清楚地了解加拿大经济这一领域的状况。
为了追踪专利权人的研发支出，专利药品价格评审委员会（PMPRB）的年度报告已成为主要数据来源。此外，金融市场和治疗局年度药品提交绩效报告也被用于研究PMPRB数据中呈现的一些模式。
大多数数据表明加拿大创新制药和生物技术行业增长良好。尽管有这种增长，但它仍落后于对更新治疗产品的需求。尽管如此，该行业能够很好地应对动荡的经济。
专利权人的研发支出是该行业健康状况的一个良好指标。它不仅提供了加拿大国内的视角，也提供了全球视角。
